(EN) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
INAVO123
NCT06790693
 Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
(EN) A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
pionERA Breast Cancer
NCT06065748
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
(EN) A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
TROPION-Breast04
NCT06112379
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
(EN) A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
TROPION-Breast05
NCT06103864
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
Biopsie des ganglions sentinelles et évidement ganglionnaire axillaire ciblé chez les patientes atteintes d’un cancer du sein avec atteinte ganglionnaire et avec résultats cliniques négatifs au niveau de l’aisselle
TADEN
NCT04671511
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
B-62/CAMBRIA-1
NCT05774951
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
(EN) A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
MK-2870-012
NCT06393374
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
(EN) A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
MAC30/BR009
NCT05879926
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Ana Lydia Tkalec
514-890-8000 poste 14186
|
(EN) Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
CFXX489A12101
NCT06562192
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Adeline Hamon
514-890-8000 poste 30737
|
Groupe d'étude en oncologie du Québec